Shares of Medgenics (MDGN +25%) soar after the company says its Infradure Biopump has received...
Wednesday, June 20, 2012, 3:08 PM ETShares of Medgenics (MDGN +25%) soar after the company says its Infradure Biopump has received an Orphan Drug Designation from the FDA to treat hepatitis D. The designation carries multiple benefits, including the availability of grant money, certain tax credits and seven years of market exclusivity, as well as the possibility of an expedited regulatory process. Seeking Alpha contributor Ray Dirks says the designation makes it a prime takeout target.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles